Rabbit Polyclonal ACADM/MCAD antibody. Suitable for IHC-P, WB, ICC/IF and reacts with Human samples. Immunogen corresponding to Recombinant Fragment Protein within Human ACADM aa 1-100.
pH: 7
Preservative: 0.01% Thimerosal (merthiolate)
Constituents: 10% Glycerol (glycerin, glycerine), 1.21% Tris, 0.75% Glycine
IHC-P | WB | ICC/IF | |
---|---|---|---|
Human | Tested | Tested | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/100 - 1/1000 | Notes Or perform heat mediated antigen retrieval with Tris-EDTA buffer pH 8. Perform heat-mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/500 - 1/3000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/100 - 1/1000 | Notes - |
Select an associated product type
Medium-chain specific acyl-CoA dehydrogenase is one of the acyl-CoA dehydrogenases that catalyze the first step of mitochondrial fatty acid beta-oxidation, an aerobic process breaking down fatty acids into acetyl-CoA and allowing the production of energy from fats (PubMed:1970566, PubMed:21237683, PubMed:2251268, PubMed:8823175). The first step of fatty acid beta-oxidation consists in the removal of one hydrogen from C-2 and C-3 of the straight-chain fatty acyl-CoA thioester, resulting in the formation of trans-2-enoyl-CoA (PubMed:2251268). Electron transfer flavoprotein (ETF) is the electron acceptor that transfers electrons to the main mitochondrial respiratory chain via ETF-ubiquinone oxidoreductase (ETF dehydrogenase) (PubMed:15159392, PubMed:25416781). Among the different mitochondrial acyl-CoA dehydrogenases, medium-chain specific acyl-CoA dehydrogenase acts specifically on acyl-CoAs with saturated 6 to 12 carbons long primary chains (PubMed:1970566, PubMed:21237683, PubMed:2251268, PubMed:8823175).
MCAD, Medium chain acyl-CoA dehydrogenase, MCADH, ACADM
Rabbit Polyclonal ACADM/MCAD antibody. Suitable for IHC-P, WB, ICC/IF and reacts with Human samples. Immunogen corresponding to Recombinant Fragment Protein within Human ACADM aa 1-100.
pH: 7
Preservative: 0.01% Thimerosal (merthiolate)
Constituents: 10% Glycerol (glycerin, glycerine), 1.21% Tris, 0.75% Glycine
ACADM also known as MCAD (medium-chain acyl-CoA dehydrogenase) is an enzyme that plays a significant role in fatty acid metabolism. It weighs approximately 44 kDa and expresses mainly in the liver heart and skeletal muscles. Functions of MCAD involve catalyzing the initial step in the mitochondrial fatty acid β-oxidation spiral specifically for the medium-chain fatty acids. This enzyme helps in the conversion of fatty acyl-CoA to trans-enoyl-CoA through dehydrogenation.
The enzyme facilitates energy production by breaking down medium-chain fatty acids within mitochondria. MCAD operates as a homotetramer complex where each subunit significantly contributes to its overall function. Such enzymatic activity is important for providing energy particularly when glycogen stores are low. Its efficient operation during fasting states indicates its importance in metabolic homeostasis.
Medium-chain acyl-CoA dehydrogenase (MCAD) is integral to the mitochondrial fatty acid beta-oxidation pathway. This pathway is a primary route for fatty acid catabolism ultimately leading to energy production in the form of ATP. MCAD's activity also relates to other fatty acid oxidation enzymes like VLCAD (very-long-chain acyl-CoA dehydrogenase) and SCAD (short-chain acyl-CoA dehydrogenase) which operate on different chain-length fatty acids cooperating to maintain energy balance.
MCAD deficiency is a common metabolic disorder that impairs the normal breakdown of fatty acids. This condition results in the accumulation of fatty acid intermediates leading to hypoketotic hypoglycemia during fasting periods. Individuals with MCAD deficiency may experience lethargy vomiting and seizures. The disorder connects with other enzymes such as LCHAD (long-chain 3-hydroxyacyl-CoA dehydrogenase) involved in similar pathways and deficiencies can result in related metabolic dysfunctions.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
10% SDS PAGE
All lanes: Western blot - Anti-ACADM/MCAD antibody (ab152115) at 1/1000 dilution
All lanes: A431 whole cell lysate at 30 µg
Predicted band size: 41 kDa, 47 kDa, 62 kDa
Immunofluorescent analysis of methanol-fixed HeLa cells labeling ACADM/MCAD with ab152115 at 1/100 dilution. Lower image shows cells co-stained with Hoechst 33342.
Immunohistochemical analysis of paraffin-embedded Human DLD1 xenograft tissue labeling ACADM/MCAD with ab152115 at 1/100 dilution.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com